We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.
- Authors
Bins, Sander; Cirkel, Geert A.; Gadellaa‐Van Hooijdonk, Christa G.; Weeber, Fleur; Numan, Isaac J.; Bruggink, Annette H.; van Diest, Paul J.; Willems, Stefan M.; Veldhuis, Wouter B.; van den Heuvel, Michel M.; de Knegt, Rob J.; Koudijs, Marco J.; van Werkhoven, Erik; Mathijssen, Ron H.J.; Cuppen, Edwin; Sleijfer, Stefan; Schellens, Jan H.M.; Voest, Emile E.; Langenberg, Marlies H.G.; de Jonge, Maja J.A.
- Abstract
Background The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high-quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, samples are freshly frozen to allow analysis by next-generation DNA/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe the first 469 image-guided biopsies collected in a large collaboration in The Netherlands (Center for Personalized Cancer Treatment) and show the utility of these specimens for NGS analysis. Patients and Methods Image-guided tumor biopsies were performed in advanced cancer patients. Samples were fresh frozen, vital tumor cellularity was estimated, and DNA was isolated after macrodissection of tumor-rich areas. Safety of the image-guided biopsy procedures was assessed by reporting of serious adverse events within 14 days after the biopsy procedure. Results Biopsy procedures were generally well tolerated. Major complications occurred in 2.1%, most frequently consisting of pain. In 7.3% of the percutaneous lung biopsies, pneumothorax requiring drainage occurred. The majority of samples (81%) contained a vital tumor percentage of at least 30%, from which at least 500 ng DNA could be isolated in 91%. Given our preset criteria, 74% of samples were of sufficient quality for biomarker discovery. The NGS results in this cohort were in line with those in other groups. Conclusion Image-guided biopsy procedures for biomarker discovery to enable personalized cancer treatment are safe and feasible and yield a highly valuable biobank. The Oncologist 2017;22:33-40 Implications for Practice: This study shows that it is safe to perform image-guided biopsy procedures to obtain fresh frozen tumor samples and that it is feasible to use these biopsies for biomarker discovery purposes in a Dutch multicenter collaboration. From the majority of the samples, sufficient DNA could be yielded to perform next-generation sequencing. These results indicate that the way is paved for consortia to prospectively collect fresh frozen tumor tissue.
- Subjects
BIOMARKERS; BIOPSY; CANCER patients; DIAGNOSTIC imaging; HISTOLOGY; GENETIC mutation; RESEARCH funding; TISSUE banks; PILOT projects; DATA analysis software; ADVERSE health care events; SEQUENCE analysis
- Publication
Oncologist, 2017, Vol 22, Issue 1, p33
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2016-0085